Sickle Cell Anemia Testing & Screening Market by Technology (Hemoglobin Electrophoresis, High-performance Liquid Chromatography (HPLC), Point-of-Care Tests), Age Group (Adult Screening, Newborn Screening, Years 1 to 25), Sector - Global Forecast 2024-2030

Sickle Cell Anemia Testing & Screening Market by Technology (Hemoglobin Electrophoresis, High-performance Liquid Chromatography (HPLC), Point-of-Care Tests), Age Group (Adult Screening, Newborn Screening, Years 1 to 25), Sector - Global Forecast 2024-2030


The Sickle Cell Anemia Testing & Screening Market size was estimated at USD 943.95 million in 2023 and expected to reach USD 1,070.69 million in 2024, at a CAGR 13.51% to reach USD 2,293.22 million by 2030.

Sickle cell anemia, known as sickle cell disease (SCD), is a genetic disorder that affects hemoglobin, the molecule in RBCs that delivers oxygen to cells throughout the body. People with sickle cell anemia have hemoglobin S, which can warp red blood cells into a sickle, or crescent, shape. These sickled cells can cause chronic pain, serious infections, and other complications because they do not flow through blood vessels easily and can block blood flow to parts of the body. Increasing prevalence of sickle cell anemia across the globe driving the adoption of testing & screening solutions. In addition, expanding healthcare infrastructure in emerging economies supports greater access to and adoption of testing and screening services. However, the high cost of genetic testing and limited reimbursement policies can impede market growth, particularly in low-income countries. Furthermore, innovations in molecular diagnostics and high-throughput screening methods are streamlining the testing process, increasing its accuracy, and reducing turnaround times.

Please Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of Sickle Cell Disease Worldwide
5.1.1.2. Ongoing Government Initiatives to Support the Diagnosis
5.1.1.3. Significant Use of High-Performance Liquid Chromatography (HPLC) Testing for Sickle Cell
5.1.2. Restraints
5.1.2.1. Diagnostic & Treatment Issues Associated with Sickle Cell Anemia
5.1.3. Opportunities
5.1.3.1. Developing a Deep Learning Framework Designed to Perform Automated Screening of Sickle Cell Anemia
5.1.3.2. Rising Focus on Development of Non-Invasive, Hand-Held, and Digital Technologies
5.1.4. Challenges
5.1.4.1. Clinical Heterogeneity and Complications Associated with SCD
5.1.4.2. Lack of Resources and Skilled Clinical Laboratory Workforce Shortages
5.2. Market Segmentation Analysis
5.2.1. Technology: Ongoing advancements hemoglobin electrophoresis for initial screening particularly in newborns
5.2.2. Sector: Corporate labs are at the forefront of innovation and technology to provide comprehensive services
5.3. Market Trend Analysis
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter’s Five Forces Analysis
5.6.1. Threat of New Entrants
5.6.2. Threat of Substitutes
5.6.3. Bargaining Power of Customers
5.6.4. Bargaining Power of Suppliers
5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis
5.9. Client Customization
6. Sickle Cell Anemia Testing & Screening Market, by Technology
6.1. Introduction
6.2. Hemoglobin Electrophoresis
6.3. High-performance Liquid Chromatography (HPLC)
6.4. Point-of-Care Tests
7. Sickle Cell Anemia Testing & Screening Market, by Age Group
7.1. Introduction
7.2. Adult Screening
7.3. Newborn Screening
7.4. Years 1 to 25
8. Sickle Cell Anemia Testing & Screening Market, by Sector
8.1. Introduction
8.2. Corporate Labs
8.3. Government Labs
8.4. Private Labs
8.5. Public-Private-Partnerships
9. Americas Sickle Cell Anemia Testing & Screening Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Sickle Cell Anemia Testing & Screening Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Sickle Cell Anemia Testing & Screening Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. USD 3 million awarded to study repurposing of blood pressure drug for SCD
12.3.2. Mylab introduces indigenous Point-of-care, Rapid Sickle Cell Anemia Test
12.3.3. Lord’s Mark Industries, IIT-Bombay partner to advance sickle cell testing in India
13. Competitive Portfolio
13.1. Key Company Profiles
13.2. Key Product Portfolio
FIGURE 1. SICKLE CELL ANEMIA TESTING & SCREENING MARKET RESEARCH PROCESS
FIGURE 2. SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. SICKLE CELL ANEMIA TESTING & SCREENING MARKET DYNAMICS
FIGURE 7. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 8. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
FIGURE 10. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2023 VS 2030 (%)
FIGURE 12. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. SICKLE CELL ANEMIA TESTING & SCREENING MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 22. SICKLE CELL ANEMIA TESTING & SCREENING MARKET, FPNV POSITIONING MATRIX, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings